49LOW

NUZ

NEURITHERA FPO [NUZ]
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0800 +0.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical48
Catalyst51
Sentiment50
Fundamental48
Momentum45
Risk Gate50
Get alerts when NUZ's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track NUZ — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Drifting lower — down 4.8% over the last 5 days
  • Critical cash runway (1.8 quarters)
  • Moderate P/S ratio (9.5x)
  • Strong revenue growth (+290%)
  • Near 52-week low (4% of range)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +290% — the top line is moving in the right direction
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-248%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 32% over the past year
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about NUZ
"What's driving NUZ's score?" "How does NUZ compare to peers?" "Key risks for NUZ?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Change of Director's Interest Notices x4
NONE Notification of Expiry of NUZOA Listed Options
NONE Neurizon presents at HEALEY ALS Platform Trial Webinar

Recent ASX Announcements

2026-03-25 Change of Director's Interest Notices x4
2026-03-19 Notification of Expiry of NUZOA Listed Options
2026-03-19 Neurizon presents at HEALEY ALS Platform Trial Webinar
2026-03-19 Section 708A Cleansing Statement
2026-03-19 Application for quotation of securities - NUZ

Key Metrics

$56.7M
Market Cap
695K
Avg Volume
0.8x
Vol Ratio
$0.08 — $0.18
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-147.1%
ROE
-248.4%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 57%
LLeader vs LaggardlaggardRS: -1
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #42 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:NUZ vs ATXNUZ vs PNVNUZ vs IMM
Scout Pro — Deeper Analysis for NUZ
Try Pro free for 30 days
Share this analysis

Track NUZ and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required